Meeting
2021 Gastrointestinal Cancers Symposium
Prospective, multicenter study of apatinib combine with TACE in treating intermediate to advanced stage HCC patients: A real-world study from China.
Authors
Hailiang Li
Henan Cancer Hospital, Zhengzhou, China
Hailiang Li , Hongtao Hu , Guangshao Cao , Gang Wu , Pengxu Ding , Zhen Li , Qiuliang Wei , Huanzhang Niu , Zukuan Chang , Jun Yin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
ChiCTR1900024030
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 282)
DOI
10.1200/JCO.2021.39.3_suppl.282
Abstract #
282
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Lenvatinib plus everolimus (LenEve) in patients with pre-treated advanced renal cell carcinoma (mRCC): Real world evidence (Relevance).
First Author: Philipp Ivanyi
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2023 ASCO Annual Meeting
Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
First Author: Baojiang Liu
Poster
2022 ASCO Annual Meeting
Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.
First Author: Lingbin Meng